Orleans Capital Management Corp LA Trims Stock Holdings in AbbVie Inc. $ABBV

Orleans Capital Management Corp LA lowered its stake in AbbVie Inc. (NYSE:ABBV) by 24.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,815 shares of the company’s stock after selling 5,110 shares during the quarter. AbbVie comprises about 2.4% of Orleans Capital Management Corp LA’s portfolio, making the stock its 11th biggest holding. Orleans Capital Management Corp LA’s holdings in AbbVie were worth $3,662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of AbbVie by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after acquiring an additional 448,554 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of AbbVie by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after purchasing an additional 924,761 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in AbbVie by 6.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after purchasing an additional 1,517,222 shares during the last quarter. Norges Bank acquired a new stake in AbbVie in the 2nd quarter valued at approximately $4,288,200,000. Finally, Raymond James Financial Inc. raised its position in AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised FY/Q1 outlook — AbbVie posted better‑than‑expected Q4 EPS and revenue and gave FY‑2026 guidance (14.37–14.57 EPS), supporting the bull case for continued top‑line and EPS growth. AbbVie (ABBV): Buy, sell, or hold post Q4 earnings?
• Positive Sentiment: Pipeline catalysts: neuroscience momentum and new approvals could drive revenue — the neuroscience unit generated ~$10.8B in 2025 and analysts see upside to ~$12.5B in 2026 as Vyalev ramps and tavapadon awaits FDA review. Will AbbVie’s Neuroscience Segment Continue to Aid Top Line in 2026?
• Positive Sentiment: Positive Phase‑3 SKYRIZI Crohn’s data strengthens the immunology franchise and expands commercial potential for risankizumab. This data is a material upside to long‑term revenue expectations for immunology products. Did Positive Phase 3 SKYRIZI Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?
• Neutral Sentiment: Analyst/market attention: some bullish writeups call ABBV a core, buy‑and‑hold dividend name and note the stock has rallied since earnings — supportive for sentiment but already reflected in recent gains. AbbVie: The only big pharma stock I’d consider a buy-and-never-sell
• Neutral Sentiment: Operational investment: AbbVie will spend $380M to expand its North Chicago campus — a long‑term capacity/R&D bet that supports future growth but increases near‑term capex. AbbVie to invest $380 million in North Chicago campus to make next generation medicines
• Negative Sentiment: Debt issuance: AbbVie completed an $8B senior notes offering, which increases leverage and raises capital‑structure risk that investors may price in, especially given the company’s already elevated payout metrics. AbbVie Completes $8 Billion Senior Notes Financing Offering
• Negative Sentiment: Dividend and leverage concerns: analysts caution that a very high payout ratio and significant debt levels warrant caution for income investors despite strong free cash flow. That raises risk of multiple compression if growth slows. Dividend Stock Analysis – Abbvie Inc.
• Negative Sentiment: Near‑term price pressure: recent sessions show ABBV underperforming the wider market on profit‑taking and macro moves, which can amplify volatility after the post‑earnings run. AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights

AbbVie Stock Performance

Shares of NYSE ABBV opened at $230.41 on Friday. The stock’s 50-day simple moving average is $224.72 and its 200-day simple moving average is $223.97. The firm has a market capitalization of $407.40 billion, a PE ratio of 97.63, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is presently 293.22%.

Insiders Place Their Bets

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.25% of the company’s stock.

Analyst Ratings Changes

ABBV has been the topic of a number of research reports. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. HSBC raised AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Evercore decreased their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.